- $183.77m
- $58.47m
- $72.76m
Brief: Compugen On Track To Present New Com701/Nivolumab Mss-Crc Data In Q4 2022
Brief: Compugen Announces Appointment Of Alberto Sessa As Chief Financial Officer
Brief: Compugen Expands Anti-PVRIG COM701 Patent Portfolio In Japan
Brief: Compugen and Bristol-Myers Squibb Terminate Master Trial Collaboration Agreement
Brief: Compugen Reports Second Quarter 2022 Results
Brief: Compugen Reports Q1 Loss Of 11 Cents Per Share
Brief: Compugen Announces CFO Departure
Brief: Compugen's Computational Discovery Leverages Single Cell Spatial Transcriptomics To Gain In-Depth Understanding Of The Tumor Microenvironment
Brief: Compugen Presents New Research Suggesting Targeting DNAM-1 Axis Holds Promise For Treatment Of Multiple Myeloma
Brief: Compugen Announces Appointment Of Dr. Mathias Hukkelhoven To Its Board Of Directors
Brief: Compugen Reports Fourth Quarter And Full Year 2021 Results
Brief: Compugen Expands Com701 Intellectual Property Portfolio With New U.S. Patent
Brief: Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the Tumor Microenvironment by COM701 at the TIGIT Therapies Digital Summit
Brief: Compugen Reports Third Quarter 2021 Results
Brief: Compugen Presents Preliminary Results From Phase 1 Dose Escalation Monotherapy Study Of Com902
Brief: Compugen Presents Preliminary Results From Phase 1/2 Dose Escalation Study of COM701 with Opdivo and BMS-986207 at SITC 2021
U.S. STOCKS ON THE MOVE-Oscar Health, Paysafe, Bumble
U.S. STOCKS ON THE MOVE-Affirm, Rivian, Bright Health
Compugen jumps on Bristol Myers Squibb's $20 mln investment